Institutional members access full text with Ovid®

Hormonal contraceptive use and risk of HIV-1 disease progression

Heffron, Reneea,b; Mugo, Nellyb,d,e; Ngure, Kennethb,d,f; Celum, Conniea,b,c; Donnell, Deborahb,g; Were, Edwinh; Rees, Heleni; Kiarie, Jamesb,d,e; Baeten, Jared M.a,b,c; for the Partners in Prevention HSVHIV Transmission Study Team

doi: 10.1097/QAD.0b013e32835ad473
Epidemiology and Social

Background: For HIV-1-infected women, hormonal contraception prevents unintended pregnancy, excess maternal morbidity, and vertical HIV-1 transmission. Hormonal contraceptives are widely used but their effects on HIV-1 disease progression are unclear.

Methods: In a prospective study among 2269 chronically HIV-1-infected women from seven countries in eastern and southern Africa and with enrollment CD4 cell counts at least 250 cells/μl, we compared rates of HIV-1 disease progression among those using and not using hormonal contraception (i.e. oral or injectable methods). The primary outcome was a composite endpoint of CD4 decline to less than 200 cells/μl, initiation of antiretroviral therapy, or death.

Results: Three hundred and seventy-two women experienced HIV-1 disease progression during 3242 years of follow-up (incidence rate = 11.5 events per 100 person-years). Rates of HIV-1 disease progression among women who were currently using and not using hormonal contraception were 8.54 and 12.31 per 100 person-years, respectively (adjusted hazard ratio 0.74, 95% confidence interval 0.56–0.98, P = 0.04). Rates were 8.58 and 8.39 per 100 person-years for the subsets using injectable and oral contraception (adjusted hazard ratio = 0.72, P = 0.04 for injectable users and adjusted hazard ratio = 0.83, P = 0.5 for oral users compared to women not using hormonal contraception). Sensitivity analyses assessing enrollment or cumulative contraceptive use during the study demonstrated risk estimates closer to 1.0 with no evidence for accelerated disease progression.

Conclusion: Among African women with chronic HIV-1 infection, use of hormonal contraception was not associated with deleterious consequences for HIV-1 disease progression.

aDepartment of Epidemiology

bDepartment of Global Health

cDepartment of Medicine, University of Washington, Seattle, USA

dDepartment of Obstetrics & Gynaecology, Kenyatta National Hospital

eDepartment of Obstetrics & Gynaecology, University of Nairobi

fJomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

gVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA

hDepartment of Reproductive Health, Moi University, Eldoret, Kenya

iWits Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand, Johannesburg, South Africa.

Correspondence to Renee Heffron, Department of Global Health, University of Washington, Box 359927, 325 Ninth Avenue, Seattle, WA 98104, USA. Tel: +1 206 520 3807; fax: +1 206 520 3831; e-mail: rheffron@uw.edu

Received 5 June, 2012

Revised 9 September, 2012

Accepted 27 September, 2012

Preliminary data from this analysis were presented at the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. March 2012. Oral abstract #21.

© 2013 Lippincott Williams & Wilkins, Inc.